Are you Dr. Rubin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham And Womens Hospital Division Of Infectious Dise
Boston, MA 02115Phone+1 617-732-8881
Summary
- Dr. Eric Rubin, MD is an infectious disease specialist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Brigham and Women's Hospital and is an Assistant Professor of Medicine (Microbiology and Molecular Genetics) at Channing Laboratory.
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1992 - 1995
- Massachusetts General HospitalResidency, Internal Medicine, 1990 - 1992
- Tufts University School of MedicineClass of 1990
Certifications & Licensure
- MA State Medical License 1992 - 2025
Publications & Presentations
PubMed
- 465 citationsComprehensive identification of conditionally essential genes in mycobacteriaChristopher M. Sassetti, Dana Boyd, Eric J. Rubin
Proceedings of the National Academy of Sciences of the United States of America. 2001-10-23 - 244 citationsMycobacterial Esx-3 is required for mycobactin-mediated iron acquisitionM. Sloan Siegrist, Meera Unnikrishnan, Matthew McConnell, Mark L. Borowsky, Tan-Yun Cheng
Proceedings of the National Academy of Sciences of the United States of America. 2009-11-03 - 140 citationsAnti-tuberculosis treatment strategies and drug development: challenges and priorities.Véronique A Dartois, Eric J Rubin
Nature Reviews. Microbiology. 2022-11-01
Authored Content
- Audio Interview: Covid-19 and Contact TracingAugust 2020
- Audio Interview: The Impact of Covid-19 on Patients with Other Diseases, with Arnold EpsteinAugust 2020
- Audio Interview: Covid-19 Vaccine DevelopmentJuly 2020
- Audio Interview: Covid-19 Vaccine DevelopmentJuly 2020
- WHO’s Next — the United States and the World Health OrganizationJuly 2020
- WHO’s Next — the United States and the World Health OrganizationJuly 2020
- Audio Interview: Acute Lung Injury in Covid-19July 2020
- Audio Interview: Acute Lung Injury in Covid-19July 2020
- Join now to see all
Press Mentions
- FDA Panel Votes to Make All COVID-19 Shots BivalentJanuary 30th, 2023
- FDA Advisory Committee Votes Unanimously in Favor of a One-Shot COVID-19 Vaccine Approach – 5 Questions AnsweredJanuary 27th, 2023
- The FDA Considers a Major Shift in the Nation's COVID Vaccine StrategyJanuary 23rd, 2023
- Join now to see all
Grant Support
- Immunology And Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2011
- Structures Of MTB Proteins Conferring Susceptibility To Known MTB InhibitorsNational Institute Of General Medical Sciences2010–2011
- Drug Targets For TuberculosisNational Institute Of Allergy And Infectious Diseases2009–2010
- 2009 Tuberculosis Drug Development GrcNational Institute Of Allergy And Infectious Diseases2009
- 2007 Grc On TB Drug DevelopmentNational Institute Of Allergy And Infectious Diseases2007
- Drug Resistance In Tuberculosis: Genetic And DynamicsNational Institute Of Allergy And Infectious Diseases2002–2005
- Virulence Factors In MycobacteriaNational Institute Of Allergy And Infectious Diseases2001–2005
- Drug Resistance In Tuberculosis--Genetic And DynamicsNational Institute Of Allergy And Infectious Diseases2001
- Virulence Factors In MycobacteriaNational Institute Of Allergy And Infectious Diseases1994–1998